Новости медицины

Літертура, Адаптована клінічна настанова, заснована на доказах, Аксіальний спондилоартрит (анкілозивний спондилоартрит)

Джерело: 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

 

  1. Zochling J, van der Heijde D, Burgos-Vargas R, ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;65:442-52.
  2. Zhang W, Doherty M, Bardin T, ; for the EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24.
  3. Mukhtyar C, Guillevin L, Cid MC, ; for the EuropeanVasculitis Study Group. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009;68:310-17.
  4. Landewe RB, Gunther K, Lukas C, et al. EULAR/EFORT recommendations for the diagnosis and initial management of patients with acute or recent onset swelling of the knee. Ann Rheum Dis 2010;69:12-19.
  5. Kowal-Bielecka O, Landewe R, Avouac J, ; EUSTAR Co-Authors. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009;68:620-8.
  6. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
  7. Dougados M, Betteridge N, Burmester GR, EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis 2004;63:1172-6.
  8. The AGREE Collaboration. Appraisal and Guidelines for Research and Evaluation (AGREE) Instrument, 2001. agreecollaboration.org (accessed Feb 2010).
  9. Moher D, Tetzlaff J, Tricco AC, et al. Epidemiology and reporting characteristics of systematic reviews. PLoS Med 2007;4:e78.
  10. Shojania KG, Sampson M, Ansari MT, Howquicklydo systematic reviewsgo out of date? A survival analysis. Ann Intern Med 2007;147:224-33.
  11. Zochling J, van der Heijde D, Dougados M, et al. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/ EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006;65:423-32.
  12. van der Heijde D, Bellamy N, Calin A, Preliminarycore sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol 1997;24:2225-9.
  13. Braun J, Pham T, Sieper J, ; ASAS Working Group. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:817-24.
  14. Braun J, Davis J, Dougados M, First update ofthe international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316-20.
  15. van der Heijde D, Sieper J, Maksymowych WP (Second) Update ofthe ASAS recommendations on the use of TNF-blockers in ankylosing spondylitis [abstract]. Arthritis and Rheumatism 2009;60(Suppl 10): 1790.
  16. Hewlett SA. Patients and clinicians have different perspectives on outcomes in arthritis. JRheumatol 2003;30:877-9.
  17. Kiltz U, van der Heijde D, Mielants H, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis: the patient version. Ann Rheum Dis 2009;68:1381-6.
  18. Gossec L, Dougados M, Phillips C, et al. Dissemination and evaluation of the ASAS/ EULAR recommendations for the management of ankylosing spondylitis: results of a study among 1507 rheumatologists. Ann Rheum Dis 2008;67:782-8.
  19. Braun J, Sieper J. [Dissemination and evaluation of ASAS/EULAR recommendations for the management of ankylosing spondylitis in Europe]. Z Rheumatol 2009;68:417-19.
  20. Braun J, Zochling J, Marker-Hermann E, [Recommendations for the management of ankylosing spodylitis after ASAS/EULAR. Evaluation in the German language area]. ZRheumatol 2006;65:728-42.
  21. Burgos-Vargas R, Abud-Mendoza C, Diaz-Jouanen E, [Treatment guidelines for ankylosing spondylitis and its effect on Mexican rheumatology]. Gac Med Mex 2009;145:41-9.
  22. Kiltz U, Feldtkeller E, Braun J. [Patient evaluation of the German version of the ASAS/ EULAR recommendations for the management of ankylosing spondylitis]. Z Rheumatol 2008;67:694-700; 702.
  23. Kiltz U, Feldtkeller E, Braun J. German patient version of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Z Rheumatol 2010;69:171-4; 176-9.
  24. Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007;369:1379-90.
  25. Rudwaleit M, Landewe R, van der Heijde D, The development ofassessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 2009;68:770-6.
  26. Rudwaleit M, van der Heijde D, Landewe R, The developmentofassessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009;68:777-83.
  27. Rudwaleit M, Jurik AG, Hermann KG, etal. Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI Group. Ann Rheum Dis 2009 ; 68:1520-7.
  28. Sieper J, Rudwaleit M, Baraliakos X, etal. The assessment of spondyloarthritis international society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009;68(Suppl 2):ii1-44.
  29. Sampaio-Barros PD, Bortoluzzo AB, Conde RA, etal. Undifferentiated spondyloarthritis: a longterm followup. J Rheumatol 2010;37:1195-9.
  30. Bennett AN, McGonagle D, O’Connor P Severity of baseline magnetic resonance imaging—evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis and Rheumatism 2008;58:3413-18.
  31. Fouque-Aubert A, Jette-Paulin L, Combescure C, Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials. Ann Rheum Dis 2010;69:1756-61.
  32. Furst DE, Keystone EC, Fleischmann R, Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis 2010;69(Suppl 1):i2-29.
  33. Zink A, Braun J, Listing J, Disability and handicap in rheumatoid arthritis and ankylosing spondylitis—results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol 2000;27:613-22.
  34. International classification of functioning, disability and health. Geneva: World Health Organization, 2001.
  35. Boonen A, Braun J, van der Horst-Bruinsma IE, The ASAS/WHO ICF core sets for ankylosing spondylitis: how to classify the impact of AS on functioning and health. Ann Rheum Dis 2010;69:102-7.
  36. Spoorenberg A, de Vlam K, van der Linden S, Radiological scoring methods in ankylosing spondylitis. Reliability and change over 1 and 2 years. J Rheumatol 2004;31:125-32.
  37. van der Heijde D, Landewe R, van der Linden S. How should treatment effect on spinal radiographic progression in patients with ankylosing spondylitis be measured? Arthritis and Rheumatism 2005;52:1979-85.
  38. Dagfinrud H, Kvien TK, Hagen KB. Physiotherapy interventions for ankylosing spondylitis. Cochrane Database SystRev 2008;1 :CD002822.
  39. Vander Cruyssen B, Ribbens C, Boonen A, The epidemiologyofankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann Rheum Dis 2007;66:1072-7.
  40. Karberg K, Zochling J, Sieper J, Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. J Rheumatol 2005;32:1290-8.
  41. Vosse D, Landewe R, van der Heijde D, Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control study. Ann Rheum Dis 2009;68:1839-42.
  42. Peters MJ, Visman I, Nielen MM, Ankylosing spondylitis: a riskfactor for myocardial infarction? Ann Rheum Dis 2010;69:579-81.
  43. Peters MJ, van Eijk IC, Smulders YM, Signs ofaccelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 2010;37:161-6.
  44. Peters MJ, Symmons DP, McCarey D, EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325-31.
  45. Conroy RM, Pyorala K, Fitzgerald AP Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart:. J 2003;24:987-1003.
  46. Cooney MT, Dudina AL, Graham IM. Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians. J Am Coll Cardiol 2009;54:1209-27.
  47. Escalas C, Trijau S, Dougados M. Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: results of a meta­analysis. Rheumatology (Oxford) 2010;49:131 7-25.
  48. van der Heijde D, Baraf HS, Ramos-Remus C, Evaluation ofthe efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis and Rheumatism 2005;52:1205-15.
  49. Sieper J, Klopsch T, Richter M, Comparisonoftwodifferentdosagesof celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Ann Rheum Dis 2008;67:323-9.
  50. Jarrett SJ, Sivera F, Cawkwell LS, MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxib. Ann Rheum Dis 2009;68:1466-9.
  51. Wanders A, Heijde D, Landewe R, Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis and Rheumatism 2005;52:1756-65.
  52. ElMiedanyY, Youssef S, Ahmed I, The gastrointestinal safetyand effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol 2006;101:311-17.
  53. Dougados M, Simon P Braun J, ASAS recommendations forcollecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. Ann Rheum Dis 2011;70:249-51.
  54. Chen J, Liu C. Sulfasalazine for ankylosing spondylitis. CochraneDatabase SystRev 2005;2: CD004800 .
  55. Braun J, Zochling J, BaraliakosX, Efficacyof sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis 2006;65:1147-53.
  56. Braun J, van der Horst-Bruinsma IE, Huang F, Clinical efficacy and safetyof etanercept versus sulfasalazine in ankylosing spondylitis patients: a randomized, double-blind study (ASCEND Trial). Arthritis and Rheumatism. Published Online First: January 2011. doi:10.1002/art.30223.
  57. Chen J, Liu C, Lin J. Methotrexate for ankylosing spondylitis . Cochrane Database Syst Rev 2006;4:CD004524.
  58. Haibel H, Brandt HC, Song IH, No efficacyof subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis 2007;66:419-21.
  59. van der Heijde D, Kivitz A, Schiff MH, ; ATLAS Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism 2006;54:2136-46.
  60. Inman RD, Davis JC Jr, Heijde D, Efficacyand safety ofgolimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis and Rheumatism 2008;58:3402-12.
  61. Braun J, McHugh N, Singh A, Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and mg twice-weekly. Rheumatology (Oxford) 2007;46:999-1004.
  62. van der Heijde D, Pangan AL, Schiff MH, ; ATLAS Study Group. Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. Ann Rheum Dis 2008;67:1218-21.
  63. Haibel H, Rudwaleit M, Listing J, Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve- week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis and Rheumatism 2008;58:1981-91.
  64. Barkham N, Keen HI, Coates LC, Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis.ArthritisandRheumatism 2009;60:946-54.
  65. Braun J, Inman R. Clinical significance of inflammatory back pain for diagnosis and screening of patients with axial spondyloarthritis. Ann Rheum Dis 2010;69:1264-8.
  66. Heiberg MS, Koldingsnes W, Mikkelsen K, The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis and Rheumatism 2008;59:234-40.
  67. van der Heijde D, Schiff MH, Sieper J, ; ATLAS Study Group. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to years: long-term results from the ATLAS trial. Ann Rheum Dis 2009;68:922-9.
  68. Davis JC Jr, van der Heijde DM, Braun J, Efficacyand safety ofup to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 2008;67:346-52.
  69. Braun J, Baraliakos X, Listing J, Persistent clinical efficacyand safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 2008;67:340-5.
  70. Braun J, Landewe R, Hermann KG, ; ASSERT Study Group. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis and Rheumatism 2006;54:1646-52.
  71. van der Heijde D, Landewe R, Einstein S, Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis and Rheumatism 2008;58:1324-31.
  72. Braun J, Baraliakos X, Listing J, Differences in the incidence offlares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis and Rheumatism 2007;57:639-47.
  73. Braun J, Baraliakos X, Listing J, Decreased incidence ofanterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis and Rheumatism 2005;52:2447-51.
  74. Braun J, Rudwaleit M, Kary S, Clinical manifestations and responsiveness to adalimumab are similar in patients with ankylosing spondylitis with and without concomitant psoriasis. Rheumatology (Oxford) 2010;49:1578-89.
  75. Rudwaleit M, Van den Bosch F, Kron M, Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther 2010;12:R117.
  76. Dougados M, Combe B, Braun J, A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial. Ann Rheum Dis 2010;69:1430-5.
  77. Cantini F, Niccoli L, Benucci M, Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study. Arthritis and Rheumatism 2006;55:812-16.
  78. Coates LC, Cawkwell LS, Ng NW, Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis. Rheumatology (Oxford) 2008;47:897-900.
  79. Pradeep DJ, Keat AC, Gaffney K, Switching anti-TNF therapy in ankylosing spondylitis. Rheumatology (Oxford) 2008;47:1726-7.
  80. de Vries MK, Wolbink GJ, Stapel SO, Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 2007;66:1252-4.
  81. de Vries MK, Brouwer E, van der Horst-Bruinsma IE, Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. Ann Rheum Dis 2009;68:1787-8.
  82. Song IH, Heldmann F, Rudwaleit M, Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis and Rheumatism 2010;62:1290-7.
  83. Song IH, Heldmann H, Rudwaleit M, Treatment ofactive ankylosing spondylitis with abatacept — an open label 24-week study. Ann Rheum Dis 2010;69(Suppl 3):60.
  84. Colina M, Ciancio G, Garavini R, etal. Combination treatment with etanercept and an intensive spa rehabilitation program in active ankylosing spondylitis. Int J Immunopathol Pharmacol 2009;22:1125-9.
  85. Vander Cruyssen B, Munoz-Gomariz E, Font P etal.; ASPECT-REGISPONSER- RESPONDIA working group. Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery. Rheumatology (Oxford) 2010;49:73-81.

 

Джерело: ASAS/EULAR recommendations for the management of ankylosing spondylitis. Zochling J, van der Heijde D, Burgos-Vargas R, et al..

 

  1. Ann Intern Med 2002;135:896-907.
  2. Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: an overview. Ann Rheum Dis 2002;61 (suppl 3):iii8-18.
  3. Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998;41:58-67.
  4. van der Heijde D, van der Linden S, Bellamy N, Calin A, Dougados M, Khan MA. Which domains should be included in a core set for endpoints in ankylosing spondylitis? Introduction to the ankylosing spondylitis module of OMERACT IV. J Rheumatol 1999;26:945-7.
  5. van der Heijde D, Calin A, Dougados M, Khan MA, van der Linden S, Bellamy N. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. J Rheumatol 1999;26:951-4.
  6. Dougados M, Betteridge N, Burmester GR, Euller-Ziegler L, Guillemin F, Hirvonen J, et al. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis 2004;63:1172-6.
  7. Zochling J, van der Heijde D, Dougados M, Braun J. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006;65:423-32.
  8. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ 1999;318:593-6.
  9. Hedges LV. Fitting continuous models to effect size data. J Educat Stat 1982;7:245-70.
  10. Cohen J. Statistical power analysis for the behavioural sciences, 2nd ed. Hillsdale NJ: Lawrence Erlbaum Associates, 1988.
  11. Whitehead A, Whitehead J. A general parametric approach to the metaanalysis of randomized clinical trials. Stat Med 1991;10:1665-77.
  12. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310:452-4.
  13. Amor B, Santos RS, Nahal R, Listrat V, Dougados M. Predictive factors for the longterm outcome of spondyloarthropathies. J Rheumatol 1994;21:1883-7.
  14. Guillemin F, Briancon S, Pourel J, Gaucher A. Long-term disability and prolonged sick leaves as outcome measurements in ankylosing spondylitis. Possible predictive factors. Arthritis Rheum 1990; 33:1001-6.
  15. Ward MM. Predictors of the progression of functional disability in patients with ankylosing spondylitis. J Rheumatol 2002;29:1420-5.
  16. Doran MF, Brophy S, MacKay K, Taylor G, Calin A. Predictors of longterm outcome in ankylosing spondylitis. J Rheumatol 2003;30:316-20.
  17. Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor a antibody infliximab. Ann Rheum Dis 2005;64:1462-6.
  18. van der Heijde D, Wanders A, Mielants H, Dougados M, Landewe R. Prediction of progression of radiographic damage over 4 years in patients with ankylosing spondylitis [abstract]. Ann Rheum Dis 2004;63(suppl 1):98.
  19. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor a blockers in ankylosing spondylitis. Ann Rheum Dis 2004;63:665-70.
  20. van der Heijde D, Bellamy N, Calin A, Dougados M, Khan MA, van der Linden S. Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol 1997;24:2225-9.
  21. van der Heijde D, van der Linden S, Dougados M, Bellamy N, Russell AS, Edmonds J. Ankylosing spondylitis: plenary discussion and results of voting on selection of domains and some specific instruments. J Rheumatol 1999;26:1003-5.
  22. Creemers MCW, Franssen MJAM, van ‘t Hof MA, Gribnau FWJ, van de Putte LBA, van Riel PLCM. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 2005;64:127-9.
  23. Braun J, Baraliakos X, Golder W, Brandt J, Rudwaleit M, Listing J, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 2003;48:1126-36.
  24. Baraliakos X, Landewe R, Hermann KG, Listing J, Golder W, Brandt J, et al. Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging. Ann Rheum Dis 2005;64:730-4.
  25. Baraliakos X, Davis J, Tsuji W, Braun J. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum 2005;52:1216-23.
  26. Dagfinrud H, Kvien TK, Hagen K. Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst Rev 2004;(4):CD002822.
  27. van Tubergen A, Landewe R, van der Heijde D, Hidding A, Wolter N, Asscher M, et al. Combined spa-exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 2001;45:430-8.
  28. van Tubergen A, Boonen A, Landewe R, Rutten-van Molken M, van der Heijde D, Hidding A, et al. Cost effectiveness of combined spa-exercise therapy in ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 2002;47:459-67.
  29. Barlow JH, Barefoot J. Group education for people with arthritis. Pt Educat Counsel 1996;27:257-67.
  30. Basler HD, Rehfisch HP. Cognitive-behavioral therapy in patients with ankylosing spondylitis in a German self-help organization. J Psychosom Res 1991;35:345-54.
  31. Krauth C, Rieger J, Bonisch A, Ehlebracht-Konig Costs and benefits of an education program for patients with ankylosing spondylitis as part of an inpatient rehabilitation programs-study design and first results. Z Rheumatol 2003;62(suppl 2):II14-16.
  32. Wanders A, van der Heijde D, Landewe R, Behier J-M, Calin A, Olivieri I, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis. Arthritis Rheum 2005;52:1756-65.
  33. Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005;64:669-81.
  34. Deeks JJ, Smith LA, Bradley Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 2002;325:619-23.
  35. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004;364:2021-9.
  36. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
  37. Solomon SD, McMurray JJV, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
  38. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:1081-91.
  39. Lewis SC, Langman MJ, Laporte JR, Matthews JN, Rawlins MD, Wiholm BE. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol 2002;54:320-6.
  40. Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? : a meta-analysis of randomised controlled trials. Ann Rheum Dis 2004;63:901-7.
  41. Maugars Y, Mathis C, Vilon P, Prost Corticosteroid injection of the sacroiliac joint in patients with seronegative spondylarthropathy. Arthritis Rheum 1992;35:564-8.
  42. Luukkainen R, Nissila M, Asikainen E, Sanila M, Lehtinen K, Alanaatu A, et al. Periarticular corticosteroid treatment of the sacroiliac joint in patients with seronegative spondylarthropathy. Clin Exp Rheumatol 1999;17:88-90.
  43. Chen J, Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2005;(2):CD004800.
  44. Kirwan J, Edwards A, Huitfeldt B, Thompson P, Currey H. The course of established ankylosing spondylitis and the effects of sulphasalazine over 3 years. Br J Rheumatol 1993;32:729-33.
  45. Lehtinen A, Leirisalo-Repo M, Taavitsainen M. Persistence of enthesopathic changes in patients with spondyloarthropathy during a 6-month follow-up. Clin Exp Rheumatol 1995;13:733-6.
  46. Benitez-Del-Castillo JM, Garcia-Sanchez J, Iradier T, Banares A. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye 2000;14(Pt 3A):340-3.
  47. Chen J, Liu C. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2004;(3):CD004524.
  48. Altan L, Bingol U, Karakoc Y, Aydiner S, Yurtkuran M, Yurtkuran M. Clinical investigation of methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 2001;30:255-9.
  49. Roychowdhury B, Bintley-Bagot S, Bulgen DY, Thompson RN, Tunn EJ, Moots RJ. Is methotrexate effective in ankylosing spondylitis? Rheumatology (Oxford) 2002;41:1330-2.
  50. Gonzalez-Lopez L, Garcia-Gonzalez A, Vazquez-Del-Mercado M, Munoz- Valle JF, Gamez-Nava JI. Efficacy of methotrexate in ankylosing spondylitis: arandomized, double blind, placebo controlled trial. J Rheumatol 2004;31:1568-74.
  51. Ortiz Z. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 1999;(4):CD000951.
  52. Maksymowych WP, Jhangri GS, Fitzgerald AA, LeClercq S, Chiu P, Yan A, et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002;46:766-73.
  53. Maksymowych WP, Jhangri GS, LeClercq S, Skeith K, Yan A, Russell AS. An open study of pamidronate in the treatment of refractory ankylosing spondylitis. J Rheumatol 1998;25:714-17.
  54. Maksymowych WP, Lambert R, Jhangri GS, LeClercq S, Chiu P, Wong B, et al. Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate J Rheumatol 2001;28:144-55.
  55. Adami S, Bhalla AK, Dorizzi R, Montesanti F, Rosini S, Salvagno G, et al. The acute-phase response after bisphosphonate CalcifTiss Int 1987;41:326-31.
  56. Wei JC, Chan TW, Lin H, Huang F, Chou C. Thalidomide for severe refractory ankylosing spondylitis: a 6-month open-label trial. J Rheumatol 2003;30:2627-31.
  57. Huang F, Gu J, Zhao W, Zhu J, Zhang J, Yu DTY. One-year open-label trial of thalidomide in ankylosing spondylitis. Arthritis Care Res 2002;47:15.
  58. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002;346:1349-56.
  59. Davis JC Jr, van der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6.
  60. Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003;48:1667-75.
  61. Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004;63:1594-600.
  62. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
  63. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis. Results of a randomized controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91.
  64. Haibel H, Brandt HC, Rudwaleit M, Listing J, Braun J, Kupper H, et al. Efficacy and safety of adalimumab in the treatment of active ankylosing spondylitis: peliminary results of an open-label, 20-week trial [abstract] Rheumatology (Oxford) 2004;50(suppl):S217.
  65. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 2005;64:229-34.
  66. Nikas SN, Alamanos Y, Voulgari PV, Pliakou XI, Papadopoulos CG,
  67. Drosos AA. Infliximab treatment in ankylosing spondylitis: an observational study. Ann Rheum Dis 2005;64:940-2.
  68. Van den Bosch F, Devinck M, Kruithof E, Baeten D, Verbruggen G, de Keyser F, et al. A prospective long-term study of the efficacy and safety of infliximab in 107 patients with spondyloarthropathy [abstract]. Rheumatology (Oxford) 2004;50(suppl):S611.
  69. Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R, et al. Persistent clinical response to the anti-TNF-(alpha) antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) 2005;44:670-6.
  70. Baraliakos X, Listing J, Brandt J, Rudwaleit M, Sieper J, Braun J. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 2005;7:R439-44.
  71. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
  72. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125-7.
  73. Marzo-Ortega H, McGonagle D, Jarrett S, Haugeberg G, Hensor E, O’Connor P, et al. Infliximab in combination with methotrexate in active ankylosing spondylitis. A clinical and imaging study. Ann Rheum Dis 2005;64:1568-75.
  74. Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:817-24.
  75. Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D, et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis
  76. 2006;65:316-20.
  77. Lee J-H, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD,
  78. Siegel JN, Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor a antagonists infliximab and etanercept. Arthritis Rheum 2002;46:2565-70.
  79. Slifman NR, Gershon SK, Lee J-H, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor a-neutralizing agents. Arthritis Rheum 2003;48:319-24.
  80. Keystone EC. Safety issues related to emerging therapies for rheumatoid arthritis. Clin Exp Rheumatol 2004;22(suppl 35):S148-50.
  81. Baeten D, Kruithof E, Van den Bosch F, Van den Bossche N, Herssens A, Mielants H, et al. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 2003;62:829-34.
  82. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, Demyelination occurring during anti-tumor necrosis factor a therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-9.
  83. Ferraccioli GF, Assaloni R, Perin A, Shakoor N, Block JA, Mohan AK, et al. Drug-induced systemic lupus erythematosus and TNF-a blockers (multiple letters). Lancet 2002;360:645-6.
  84. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002;359:579-80.
  85. Cairns AP, Duncan MKJ, Hinder AE, Taggart AJ. New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann Rheum Dis 2002;61:1031-2.
  86. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT, Anti-TNF therapy against congestive heart failure investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133-40.
  87. Coletta AP, Clark AL, Banarjee P, Cleland JG. Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH. EurJ Heart Failure 2002;4:559-61.
  88. Wolfe F, Michaud MS. Congestive heart failure in rheumatoid arthritis: rates, predictors and the effect of anti-TNF therapy. Am J Med 2004;116:311.
  89. Kobelt G, Andlin-Sobocki P, Brophy S, Jonsson L, Calin A, Braun J. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade). Rheumatology (Oxford) 2004;43:1158-66.
  90. Singh G, Tandon N, Bala M. A cost efficacy analysis on anti-TNF therapy in ankylosing spondylitis [abstract]. Arthritis Rheum 2004;50(suppl):S613.
  91. Sweeney S, Gupta R, Taylor G, Calin A. Total hip arthroplasty in ankylosing spondylitis: outcome in 340 patients. J Rheumatol 2001;28:1862-6.
  92. Furnes O, Lie SA, Espehaug B, Vollset SE, Engesaeter LB, Havelin LI. Hip disease and the prognosis of total hip replacements. A review of 53,698 primary total hip replacements reported to the Norwegian Arthroplasty Register 1987-99. J Bone Joint Surg Br 2001;83:579-86.
  93. Brinker MR, Rosenberg AG, Kull L, Cox DD. Primary noncemented total hip arthroplasty in patients with ankylosing spondylitis: clinical and radiographic results at an average follow-up period of 6 years. J Arthroplasty 1996;11:802-12.
  94. Bhan S, Malhotra R. Bipolar hip arthroplasty in ankylosing spondylitis. Arch Orthop Trauma Surg 1996;115:94-9.
  95. Diaz de Rada P, Barroso-Diaz JL, Valenti JR. Follow -up of the outcome of hip arthroplasty in patients with ankylosing spondylitis. Rev Ortop Traumatol 2004;48:340-4.
  96. Sochart DH, Porter ML. Long-term results of total hip replacement in young patients who had ankylosing spondylitis. Eighteen to thirty-year results with survivorship oint Surg Am 1997;79:1181-9.

 

Джерело: New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS)

 

  1. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification spondylarthropathy. Arthritis Rheum 1991;34:1218–27.
  2. Amor B, Dougados M, Mijiyawa M. Crite`res de classification des spondylarthropathies. Rev Rhum 1990;57:85–9.
  3. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361–8.
  4. Khan MA, van der Linden SM. A wider spectrum of spondyloarthropathies. Semin Arthritis Rheum 1990;20:107–13.
  5. Khan MA, van der Linden SM, Kushner I, Valkenburg HA, Cats A. Spondylitic disease without radiological evidence of sacroiliitis in relatives of HLA-B27 positive patients. Arthritis Rheum 1985;28:40–3.
  6. Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum 2005;52:1000–8.
  7. Braun J, Bollow M, Eggens U, Konig H, Distler A, Sieper J. Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum 1994;37:1039–45.
  8. Grigoryan M, Roemer FW, Mohr A, Genant HK. Imaging in spondyloarthropathies. Curr Rheumatol Rep 2004;6:102–9.
  9. Oostveen J, Prevo R, den Boer J, van de Laar M. Early detection of sacroiliitis on magnetic resonance imaging and subsequent development of sacroiliitis on plain radiography. A prospective, longitudinal study. J Rheumatol 1999;26:1953–8.
  10. Bennett AN, McGonagle D, O’Connor P, Hensor EM, Sivera F, Coates LC, et al. Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum 2008;58:3413–18.
  11. Rudwaleit M, Landewe´ R, van der Heijde D, Listing J, Brandt J, Braun J, et al. The Development of Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axial spondyloarthritis (part I): classification of paper by expert opinion including uncertainty appraisal. Ann Rheum Dis 2009; in press.
  12. Calin A, Porta J, Fries JF, Schurman DJ. Clinical history as a screening test for ankylosing spondylitis. JAMA 1977;237:2613–14.
  13. Rudwaleit M, Metter A, Listing J, Sieper J, Braun J. Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum 2006;54:569–78.
  14. Sieper J, van der Heide D, Landewe´ R, Brandt J, Collantes-Estevez E, Dijkmans B, et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis 2009;68:784–8.
  15. Mau W, Zeidler H, Mau R, Majewski A, Freyschmidt J, Stangel W, et al. Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year follow-up. J Rheumatol 1988;15:1109–14.
  16. Rudwaleit M, Haibel H, Baraliakos X, Listing J, Maerker-Hermann E, Zeidler H, et al. The early disease stage in axial spondyloarthritis – results from the German Spondyloarthritis Inception Cohort (GESPIC). Arthritis Rheum 2009;60:717–27.
  17. Haibel H, Rudwaleit M, Listing J, Heldmann F, Wong RL, Kupper H, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 2008;58:1981–91.
  18. Barkham N, Keen HI, Coates LC, O’Connor P, Hensor E, Fraser AD, et al. Clinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 2009;60:946–54.
  19. Singh JA, Solomon DH, Dougados M, Felson D, Hawker G, Katz P, et al. Classification and Response Criteria Subcommittee of the Committee on Quality Measures, American College of Rheumatology. Development of classification and response criteria in rheumatic diseases. Arthritis Rheum 2006;55:348–52.
  20. Dougados M, Gossec L. Classification criteria for rheumatic diseases: why and how? Arthritis Rheum 2007;57:1112–15.
  21. Rudwaleit M, van der Heijde D, Khan MA, Braun J, Sieper J. How to diagnose axial spondyloarthritis early. Ann Rheum Dis 2004;63:535–43.

Комментировать

Нажмите для комментария

Здравствуйте,
Выйти

Мы на Facebook